Citations

Clear

626 citation(s) found for "Mehta, SH".

Patient- versus clinician-reported symptoms in the POLARIX study.
Thompson, Carrie A. , Mehta-Shah, Neha, Flowers, Christopher R. , Tilly, Hervé , Chua, Neil , Miall, Fiona , Tsai, Cheng‐Hong , Craine, Veronica, Campinha‐Bacote, Avrita, Hirata, Jamie , Lee, Calvin , Sugidono, Matthew , Friedberg, Jonathan W. , Tsai, Xavier Cheng-Hong , Mehta–Shah, Neha , Salles, Gilles , Casasnovas, Olivier , Kim, Tae Min , Nasta, Sunita , Lee, Seung‐Tae

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 12100-12100

10.1200/jco.2023.41.16_suppl.12100 Get It

12100 Background: The safety profiles of novel agents are mainly based on clinician-reported adverse events (AEs) from clinical trials. Patient-reported outcomes (PROs) may better represent the treatment burden experienced by patients (pts) compared with clinician-reported AEs. Using data from POLARIX, a double-blind, placebo-controlled, randomized Phase 3 international study (NCT03274492), we previously presented PRO and clinician-reported data showing similar rates of neuropathy (Trněný et al. 2022). Here, we evaluate the reporting of other common symptoms using PRO and clinician-reported data in POLARIX. Methods: POLARIX methods were previously described (Tilly et al. 2022); this analysis included all pts with PRO data. PRO and clinician-reported data described the incidence and severity of fatigue, constipation, diarrhea, nausea, and vomiting. Clinician-reported severity grading was based on the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0. PROs were collected using the European Organisation Research and Treatment of Cancer Quality of Life-Core 30 questionnaire (EORTC QLQ-C30), which was administered to pts at clinic visits on Day 1 of Cycles 1 (baseline), 2, 3, and 5, and end of treatment (EOT). PRO severity scores included ‘A little’, ‘Quite a bit’, and ‘Very much’. Results: Overall, 825 pts were evaluable. From baseline to EOT, PROs showed a higher incidence of symptoms compared with clinicians for fatigue (98% vs 27%), constipation (68% vs 29%), diarrhea (56% vs 26%), nausea (58% vs 40%), and vomiting (24% vs 15%). PRO severity scores of ‘Quite a bit’ or ‘Very much’ were reported in 33% of pts for fatigue, 29% for constipation, 17% for diarrhea, 19% for nausea, and 7% for vomiting. Clinicians reported Grade ≥2 symptoms in 11% of pts for fatigue, 11% for constipation, 11% for diarrhea, 14% for nausea, and 6% for vomiting. Conclusions: In POLARIX, pts reported a higher incidence and severity of symptoms compared with clinicians. Although distinct scales were used, the differences in symptom rates reported by pts and clinicians were clinically meaningful. These data may have implications for symptom management, including physician evaluation and communication of symptom expectations for pts. Reporting of symptoms by PROs should be incorporated into clinical trials as an adjunct to standard AE reporting to better characterize the patient experience. Clinical trial information: NCT03274492 . [Table: see text]
Importance of clinical decision making in precision oncology: Discordance in recommendation between next generation sequencing test vendor and molecular tumour board in India.
Davis, Sissmol , I, Anu R , Suryavanshi, Moushumi , Dawood, Shaheenah , Panda, Pankaj Kumar , Nag, Shona, Das, Arunangshu, Rohatgi, Nitesh, Shah, Riyaz , Thampy, Cherian, Mukherji, Deborah , Shilpakar, Ramila , Mullapally, Sujith Kumar, Mathew, Aju , Sirohi, Bhawna , Dawood, Shaheenah , Popat, Sanjay , Parikh, Aparna R. , Yadav, Siddhartha , Mehta, Prashant , Singh, Randeep K.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e15050-e15050

10.1200/jco.2023.41.16_suppl.e15050 Get It

e15050 Background: Molecular tumour boards (MTB) facilitate discussions among medical professionals, scientists, bioinformaticians and geneticists for clinical application of precision oncology, via interpretation of various genomic sequencing studies, most commonly Next Generation Sequencing (NGS). NGS test vendor recommendation may differ from the MTB recommendations. We aim to study the discordance rate between these recommendations. Methods: MTB discussions between April 1, 2021 and December 31, 2021, were retrospectively evaluated. MTBs which assessed NGS reports with or without significant genetic mutations but with drug recommendations were included. NGS testing was done with multiple vendors. Patients from all over India, Nepal, Bangladesh, Dubai and Abu Dhabi were discussed. We excluded MTBs which assessed NGS data without any drug recommendations. We compared therapeutic recommendations provided in the NGS report with the first-choice recommendation in the MTB discussion. Recommendation discordance was defined as disagreement between the NGS recommendation and the first MTB recommendation that either instructed its implementation either immediately or on disease progression. Results: 70 MTB data was studied. 49 MTBs assessing NGS reports of 49 unique patients (median age 54 years; range, 32-82) were included in the study. 13 patients had lung cancer, 10 colorectal, 6 breast, 7 hepatopancreatobiliary, 4 carcinoma of unknown primary and 9 others. 17 did not provide any treatment recommendations and hence were excluded. 4 were discussions based on NGS reports previously discussed in an MTB that was already included in the study, hence were excluded. Recommendation discordance rate was 49% (24 of 49). Conclusions: To our knowledge, this is the first study that assessed discordance rate in recommendations between NGS report and MTB from a low- and middle-income country setting. Accurate clinical translation of complex genomic data is at the forefront of personalized cancer care.
RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade gliomas in adults.
Wen, Patrick Y. , Groot, John Frederick De, Lassman, Andrew B. , Molinaro, Annette M. , Shankar, Lalitha , Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , Wen, Patrick Yung , Bent, Martin J. van den , Youssef, Gilbert , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Weller, Michael , Galanis, Evanthia , Barboriak, Daniel P. , Gilbert, Mark R. , Huang, Raymond Y. , Mehta, Minesh P. , Molinaro, Annette M. , Preusser, Matthias , Wick, Wolfgang

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 2017-2017

10.1200/jco.2023.41.16_suppl.2017 Get It

2017 Background: Response Assessment in Neuro-Oncology (RANO) criteria for high-grade and low-grade glioma (HGG and LGG) were developed to improve reliability of response assessment in glioma trials. Several limitations of the original RANO criteria have been reported. Methods: To address limitations of the original RANO criteria, a large cohort of patients with newly diagnosed and recurrent glioblastoma were evaluated comparing RANO-HGG with modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria to inform the following proposed updates (RANO 2.0). Results: Based on the 2021 WHO classification of glioma, we recommend a single common set of criteria for all gliomas regardless of WHO grade and IDH mutational status. These criteria will be used for all trials regardless of the treatment modalities being evaluated. In newly diagnosed glioblastoma, the post-radiotherapy MRI, usually obtained approximately 4 weeks after completion of radiotherapy, rather than the post-surgical MRI as proposed in original RANO criteria, will be used as the baseline for comparison of subsequent scans. Since the incidence of pseudoprogression is high in the first 3 months following radiotherapy, confirmation of progression during this period with a repeat MRI (in 4-8 weeks) will be required for determining radiographic progression of disease (PD) if the patient is clinically stable. However, confirmation scans are not mandatory after this period nor for recurrent tumors since these scans do not appear to improve reliability in determining progression. For agents with a high likelihood of producing pseudoprogression such as viral therapies and some other immunotherapies, mandatory confirmation of progression with a repeat MRI is an option. The primary measurement will remain the 2-dimensional maximum cross-sectional area of tumor as the simplest method, but where resources are available, volumetric measurements are an option. For IDH wild-type tumors with contrast enhancement, non-enhancing tumor will no longer be evaluated with the possible exception of patients receiving antiangiogenic therapies. However, in tumors with a significant non-enhancing component, both the contrast enhancing and non-enhancing components will be evaluated as target lesions. Conclusions: We hope that these and other proposed changes by the RANO working group will improve response assessment in glioma clinical trials and help the development of more effective therapy for patients.
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma
Stuver, Robert , Horwitz, Steven M. , Advani, Ranjana H. , Lee, Hun Ju , Mehta–Shah, Neha , Zain, Jasmine , Haverkos, Bradley M. , Lechowicz, Mary Jo , Moskowitz, Alison J. , Pham, Luu Q., Leyden, E., Ansell, Stephen M. , Lunning, Matthew A. , Lee, Hun Ju , Mehta-Shah, Neha , Ansell, Stephen M , Advani, Ranjana H , Horwitz, Steven M , Stuver, Robert , Vose, Julie M. , Leyden, Elizabeth

Mayo Clinic

British Journal of Haematology | May 22, 2023 | Volume: 202 | Issue: 3 | Pages: 525-529

10.1111/bjh.18885 | PMID 37217196 Get It

SummaryThere remains no one standard induction for nodal‐based peripheral T‐cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as a novel induction strategy. Patients received CHOEP at standard doses in combination with 10 mg of lenalidomide on days 1–10 of a 21‐day cycle for six cycles of therapy followed by observation, high‐dose therapy with autologous stem cell rescue, or maintenance lenalidomide per provider preference. Among 39 patients evaluable for efficacy, the objective response rate after six cycles was 69%, with complete response in 49%, partial response in 21%, stable disease in 0% and progressive disease in 13%. Thirty‐two patients (82%) completed full induction, and seven patients (18%) discontinued for toxicity, primarily hematologic. Any grade hematologic toxicity occurred in over 50% of patients, with grade 3 or 4 febrile neutropenia occurring in 35% of patients despite mandated growth factors. With a median followup of surviving patients of 21.3 months, the estimated 2‐year progression‐free and overall survival were 55% (95% CI 37%–70%) and 78% (95% CI 59%–89%), respectively. In sum, six cycles of lenalidomide plus CHOEP resulted in a modest response rate primarily due to hematologic toxicity, which prevented all patients from completing planned induction.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Mehta, Neil , Dawson, Laura A. , Jou, Janice H. , Kulik, Laura , Marrero, Jorge A. , Rilling, William S., Singal, Amit G. , Llovet, Josep M. , Yarchoan, Mark , Heimbach, Julie K. , Agopian, Vatche G. , Mendiratta-Lala, Mishal , Brown, Daniel B. , Goyal, Lipika , Wei, Alice C. , Taddei, Tamar H

Mayo Clinic

Hepatology | May 18, 2023 | Volume: 78 | Issue: 6 | Pages: 1922-1965

10.1097/hep.0000000000000466 | PMID 37199193 Get It

Outpatient Antibiotic Use is Not Associated with an Increased Risk of First-Time Symptomatic Kidney Stones
Thongprayoon, Charat , Vaughan, Lisa E. , Frazee, Erin N. , Mehta, Ramila A. , Koo, Kevin , Schulte, Phillip J. , Lieske, John C. , Rule, Andrew D. , Rule, Andrew D , Lieske, John C , Thongprayoon, Charat

Mayo Clinic

Journal of the American Society of Nephrology | May 15, 2023 | Volume: 34 | Issue: 8 | Pages: 1399-1408

10.1681/asn.0000000000000155 | PMID 37184480 Get It

Significance Statement Antibiotics modify human microbiomes and may contribute to kidney stone risk. In a population-based case-control study using 1247 chart-validated first-time symptomatic kidney stone formers and 4024 age- and sex-matched controls, the risk of kidney stones was transiently higher during the first year after antibiotic use. However, this risk was no longer evident after adjustment for comorbidities and excluding participants with prior urinary symptoms. Findings were consistent across antibiotic classes and the number of antibiotic courses received. This suggests that antibiotics are not important risk factors of kidney stones. Rather, kidney stones when they initially cause urinary symptoms are under-recognized, resulting in antibiotic use before a formal diagnosis of kidney stones ( i.e. , reverse causality). Background Antibiotics modify gastrointestinal and urinary microbiomes, which may contribute to kidney stone formation. This study examined whether an increased risk of a first-time symptomatic kidney stone episode follows antibiotic use. Methods A population-based case-control study surveyed 1247 chart-validated first-time symptomatic kidney stone formers with a documented obstructing or passed stone (cases) in Olmsted County, Minnesota, from 2008 to 2013 and 4024 age- and sex-matched controls. All prescriptions for outpatient oral antibiotic use within 5 years before the onset of symptomatic stone for the cases and their matched controls were identified. Conditional logistic regression estimated the odds ratio (OR) of a first-time symptomatic kidney stone across time after antibiotic use. Analyses were also performed after excluding cases and controls with prior urinary tract infection or hematuria because urinary symptoms resulting in antibiotic prescription could have been warranted because of undiagnosed kidney stones. Results The risk of a symptomatic kidney stone was only increased during the 1-year period after antibiotic use (unadjusted OR, 1.31; P = 0.001), and this risk was attenuated after adjustment for comorbidities (OR, 1.16; P = 0.08). After excluding cases and controls with prior urinary symptoms, there was no increased risk of a symptomatic kidney stone during the 1-year period after antibiotic use (unadjusted OR, 1.04; P = 0.70). Findings were consistent across antibiotic classes and the number of antibiotic courses received. Conclusions The increased risk of a first-time symptomatic kidney stone with antibiotic use seems largely due to both comorbidities and prescription of antibiotics for urinary symptoms. Under-recognition of kidney stones that initially cause urinary symptoms resulting in antibiotic use may explain much of the perceived stone risk with antibiotics ( i.e. , reverse causality).
Intrathecal Dexamethasone in Febrile Infection–Related Epilepsy Syndrome
Mehta, Niyati P., Sawdy, Rachel, Overlee, Brittany L., Johnson, Renee K., Howe, Charles L. , Farias‐Moeller, Raquel , Mehta, Niyati , Maloney, Kathleen, Howe, Charles L , Farias-Moeller, Raquel , Mehta, Niyati P., Maloney, Kathleen H.

Mayo Clinic

Neurology Clinical Practice | May 12, 2023 | Volume: 13 | Issue: 3 | Pages: No page available

10.1212/cpj.0000000000200153 | PMID 37197372 Get It

Type of donor liver transplant does not affect pregnancy outcomes—a systematic review and meta-analysis
Osman, Karim T. , Nayfeh, Tarek , Alrukby, Judy, Mehta, Neev , Elkhabiry, Lina, Spencer, Carol, Aby, Elizabeth S. , Nayfeh, Tarek

Mayo Clinic

Liver Transplantation | May 4, 2023 | Volume: 29 | Issue: 12 | Pages: 1304-1312

10.1097/lvt.0000000000000168 | PMID 37141916 Get It

Liver transplant (LT) has become increasingly common among reproductive-aged women. The effect of the type of liver donor, either a living donor LT (LDLT) or a deceased donor LT, on pregnancy outcomes is unknown. As such, we aim to review the available literature and assess obstetric, pregnancy, or delivery outcomes in LDLT. We conducted a comprehensive literature review of MEDLINE, EMBASE, Cochrane, and Scopus databases. Random-effect meta-regression assessed the association between the percentage of women who underwent LDLT (independent variable) and the proportion of outcomes. Meta-regression results were expressed as a regression coefficient, which transforms the proportion of outcomes of interest associated with a 1% increase in the percentage of LDLT patients. A value of 0 denotes no relationship between the outcomes and LDLT. A total of 6 articles (438 patients) were included, with a total of 806 pregnancies. Eighty-eight (20.09%) patients underwent LDLT. None of the studies segregated the data based on the type of donor LT. The median time from LT to pregnancy was 4.86 (4.62–5.03) years. Twelve (1.5%) stillbirths were reported. LDLT was statistically significantly associated with a higher rate of stillbirths (coefficient 0.002, p < 0.001; I2 0%). The type of donor LT was not associated with an increased risk of other obstetric, pregnancy, or delivery complications. This is the first meta-analysis to evaluate the effect of the type of donor LT on pregnancy outcomes. This study highlights the lack of robust literature addressing this important topic. The results suggest that pregnancy outcomes after LDLT and deceased donor LT are comparable. Despite LDLT being statistically significantly associated with a higher rate of stillbirths, the association is weak and is unlikely to be clinically significant.
Primary Pulmonary Myxoid Sarcoma in a Heart Transplant Recipient
KIANI, AHMED Z, Mehta, A., Butt, Y., Thomas, Justin M.

Mayo Clinic

C76. SARCOMA AND NEUROENDOCRINE TUMORS: CASES IN THORACIC ONCOLOGY | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A5874-A5874

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5874 Get It